Wen Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wen Xu has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Mun Fei Yam
School of Pharmaceutical Sciences, Universiti Sains Malaysia
7 shared publications - Shuisheng Wu
College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China
7 shared publications Wei Xu
Collage of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China
7 shared publications- Lixia Chen
Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China
5 shared publications - Hua Li
Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China
4 shared publications - Wei Xu
Institute of Structural Pharmacology & TCM Chemical Biology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China
4 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by Wiley in Advanced Science
- p. e78310
Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55–ESCRT‐Associated Vesicular Damage Clearance
Oxaliplatin (L‐OHP) is a first‐line chemotherapeutic agent for advanced colorectal cancer (CRC) and postoperative adjuvant therapy. However, acquired L‐OHP resistance remains a clinical obstacle. Here, we identify Tubocapsenolide A (TA), a natural withanolide isolated from Tubocapsicum anomalum , as a promising antitumor agent that suppresses CRC growth and sensitizes L‐OHP‐resistant CRC to L‐OHP. Using a PROTAC‐based target deconvolution strategy, we identify PLK1 as a direct molecular target of TA. PLK1 is elevated in L‐OHP‐resistant CRC and is associated with reduced patient sensitivity to L‐OHP. Mechanistically, elevated PLK1 promotes CEP55 Ser436 phosphorylation and facilitates ESCRT recruitment to nuclear and mitochondrial budding sites. This process facilitates the clearance of L‐OHP‐induced damaged components through nuclear budding and TOM20 − /PDH + mitochondrial‐derived vesicles, thereby contributing to organelle homeostasis and cell survival. By inhibiting PLK1, TA interferes with this vesicle‐associated damage clearance process, leading to intracellular accumulation of damaged components. This damage accumulation is accompanied by nucleolar stress and mitochondrial dysfunction, ultimately contributing to cell death. Collectively, our findings identify a previously unappreciated role of the PLK1–CEP55–ESCRT axis in vesicle‐associated damage clearance during L‐OHP resistance and support this axis as a potential therapeutic target. TA represents a promising lead compound for overcoming L‐OHP resistance in CRC.
- 18 October 2026
- Published by Wiley in Advanced Science
- p. e78310
Open AccessTubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55–ESCRT‐Associated Vesicular Damage Clearance
Oxaliplatin (L‐OHP) is a first‐line chemotherapeutic agent for advanced colorectal cancer (CRC) and postoperative adjuvant therapy. However, acquired L‐OHP resistance remains a clinical obstacle. Here, we identify Tubocapsenolide A (TA), a natural withanolide isolated from Tubocapsicum anomalum , as a promising antitumor agent that suppresses CRC growth and sensitizes L‐OHP‐resistant CRC to L‐OHP. Using a PROTAC‐based target deconvolution strategy, we identify PLK1 as a direct molecular target of TA. PLK1 is elevated in L‐OHP‐resistant CRC and is associated with reduced patient sensitivity to L‐OHP. Mechanistically, elevated PLK1 promotes CEP55 Ser436 phosphorylation and facilitates ESCRT recruitment to nuclear and mitochondrial budding sites. This process facilitates the clearance of L‐OHP‐induced damaged components through nuclear budding and TOM20 − /PDH + mitochondrial‐derived vesicles, thereby contributing to organelle homeostasis and cell survival. By inhibiting PLK1, TA interferes with this vesicle‐associated damage clearance process, leading to intracellular accumulation of damaged components. This damage accumulation is accompanied by nucleolar stress and mitochondrial dysfunction, ultimately contributing to cell death. Collectively, our findings identify a previously unappreciated role of the PLK1–CEP55–ESCRT axis in vesicle‐associated damage clearance during L‐OHP resistance and support this axis as a potential therapeutic target. TA represents a promising lead compound for overcoming L‐OHP resistance in CRC.
- 24 August 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (17) , 4950-4955
An aggregation-induced electrochemiluminescence sensor for ochratoxin A detection integrating CRISPR-Cas12a and tetrahedral DNA nanostructures
This work demonstrates, for the first time, an aggregation-induced electrochemiluminescence sensor for ochratoxin A detection integrating CRISPR-Cas12a and tetrahedral DNA nanostructures.
- 24 August 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (17) , 4950-4955
An aggregation-induced electrochemiluminescence sensor for ochratoxin A detection integrating CRISPR-Cas12a and tetrahedral DNA nanostructures
This work demonstrates, for the first time, an aggregation-induced electrochemiluminescence sensor for ochratoxin A detection integrating CRISPR-Cas12a and tetrahedral DNA nanostructures.
- Open Access
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1830589
Aconitum carmichaelii: a clinical-regulatory synthesis of traditional use, toxicological evidence, and global safety governance
Aconitum carmichaelii Debeaux (Ranunculaceae), commonly used as Aconiti Lateralis Radix Praeparata (Fuzi), is a clinically important but highly toxic herb in traditional Chinese medicine. Despite long-standing use for cardiovascular, rheumatologic, gastrointestinal, and pain-related conditions, its application is constrained by a narrow therapeutic index, variable processing practices, and recurrent reports of poisoning. Given the substantial number of existing reviews on aconite, this article is deliberately positioned as a clinical-regulatory synthesis rather than another general phytochemical or mechanistic overview. It complements recent integrative-toxicology reviews by linking phytochemistry, pharmacodynamics, toxicodynamics, clinical poisoning patterns, evidence hierarchy, processing variability, analytical quality control, and international regulatory governance. A structured literature search, informed by PRISMA 2020 reporting principles, was conducted across PubMed, CNKI, Web of Science, Scopus, and ScienceDirect for English- and Chinese-language publications available up to 31 December 2025, supplemented by pharmacopoeial and regulatory documents. Evidence was synthesised narratively because of heterogeneity in study design, model systems, preparations, and outcome measures. Diterpenoid alkaloids, especially diester diterpenoid alkaloids, are central to both bioactivity and toxicity. Preclinical studies suggest cardiotonic, anti-inflammatory, analgesic, immunomodulatory, and anti-tumour effects, but many claims remain based on in vitro or animal models, isolated compounds, or multi-herb formulas in which Fuzi-specific effects cannot be separated. In contrast, clinical poisoning data consistently link excessive or inadequately processed exposure to cardiotoxicity and neurotoxicity through ion-channel disruption, calcium overload, mitochondrial dysfunction, oxidative stress, and apoptosis. The strongest human evidence relates to standardised proprietary formulations tested in larger controlled trials, whereas most decoction-based reports remain small, adjunctive, or methodologically limited. Overall, the novel contribution of this review is a practice-oriented risk-benefit framework that connects mechanistic plausibility with real-world clinical toxicology, quality-control checkpoints, and global safety governance.
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1830589
Open AccessAconitum carmichaelii: a clinical-regulatory synthesis of traditional use, toxicological evidence, and global safety governance
Aconitum carmichaelii Debeaux (Ranunculaceae), commonly used as Aconiti Lateralis Radix Praeparata (Fuzi), is a clinically important but highly toxic herb in traditional Chinese medicine. Despite long-standing use for cardiovascular, rheumatologic, gastrointestinal, and pain-related conditions, its application is constrained by a narrow therapeutic index, variable processing practices, and recurrent reports of poisoning. Given the substantial number of existing reviews on aconite, this article is deliberately positioned as a clinical-regulatory synthesis rather than another general phytochemical or mechanistic overview. It complements recent integrative-toxicology reviews by linking phytochemistry, pharmacodynamics, toxicodynamics, clinical poisoning patterns, evidence hierarchy, processing variability, analytical quality control, and international regulatory governance. A structured literature search, informed by PRISMA 2020 reporting principles, was conducted across PubMed, CNKI, Web of Science, Scopus, and ScienceDirect for English- and Chinese-language publications available up to 31 December 2025, supplemented by pharmacopoeial and regulatory documents. Evidence was synthesised narratively because of heterogeneity in study design, model systems, preparations, and outcome measures. Diterpenoid alkaloids, especially diester diterpenoid alkaloids, are central to both bioactivity and toxicity. Preclinical studies suggest cardiotonic, anti-inflammatory, analgesic, immunomodulatory, and anti-tumour effects, but many claims remain based on in vitro or animal models, isolated compounds, or multi-herb formulas in which Fuzi-specific effects cannot be separated. In contrast, clinical poisoning data consistently link excessive or inadequately processed exposure to cardiotoxicity and neurotoxicity through ion-channel disruption, calcium overload, mitochondrial dysfunction, oxidative stress, and apoptosis. The strongest human evidence relates to standardised proprietary formulations tested in larger controlled trials, whereas most decoction-based reports remain small, adjunctive, or methodologically limited. Overall, the novel contribution of this review is a practice-oriented risk-benefit framework that connects mechanistic plausibility with real-world clinical toxicology, quality-control checkpoints, and global safety governance.
- 14 January 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (5) , 1325-1331
An “off–on” electrochemiluminescence biosensor based on CRISPR-Cas12a for ultrasensitive determination of aflatoxin B1
An aggregation-induced electrochemiluminescence sensor integrated CRISPR-Cas12a system is firstly reported for the detection of aflatoxin B1 (AFB1), demonstrating excellent analysis performance.
- 14 January 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (5) , 1325-1331
An “off–on” electrochemiluminescence biosensor based on CRISPR-Cas12a for ultrasensitive determination of aflatoxin B1
An aggregation-induced electrochemiluminescence sensor integrated CRISPR-Cas12a system is firstly reported for the detection of aflatoxin B1 (AFB1), demonstrating excellent analysis performance.
- Open Access
- 18 November 2025
- Published by Frontiers Media SA in Frontiers in Plant Science
- Vol. 16
Dynamic proteomics reveals that endosperm weakening plays a critical role during seed germination in Polygonatum cyrtonema Hua
Introduction: Polygonatum cyrtonema Hua, a valued Chinese medicinal herb, faces challenges in cultivation and seedling quality due to seed dormancy, a combinational type resulting from multiple factors whose molecular mechanisms remain unclear. Methods: This study employed iTRAQ-based proteomics, transcriptomics, and hormone profiling to analyze three key germination stages (S1, pulp removal and initial imbibition. S2, radicle emergence through the seed coat. S3, transition phase between primary root elongation and cotyledon emergence). Results: Morphological observations indicated gradual endosperm weakening and embryo development during germination. Transcriptomics highlighted 30 enriched pathways, notably plant hormone signaling and starch and sucrose metabolism. Proteomics revealed consistent enrichment of FOG: RRM domain, aspartyl protease, and β-fructofuranosidase across comparisons. Hormone assays showed decreases in ABA, bioactive GAs, IAA, JA, and SA from S1 to S3, with a marked increase in the bioactive GAs/ABA ratio. Integrated omics emphasized metabolism and hormone signal transduction. Key enzymes in starch and sucrose metabolism (e.g., β-fructofuranosidase, α-xylosidase, β-D-xylosidase, and β-glucosidase) increased, supporting energy conversion and endosperm weakening. Conversely, ABA-related proteins (PYL4, PP2C) decreased. Sucrose synthase, involved in ABA-GA antagonism, also declined. Discussion: These results underscore synergistic endosperm weakening and hormonal regulation during P. cyrtonema seed germination, offering new insights for improving germination in species constrained by endosperm strength.
- 18 November 2025
- Published by Frontiers Media SA in Frontiers in Plant Science
- Vol. 16
Open AccessDynamic proteomics reveals that endosperm weakening plays a critical role during seed germination in Polygonatum cyrtonema Hua
Introduction: Polygonatum cyrtonema Hua, a valued Chinese medicinal herb, faces challenges in cultivation and seedling quality due to seed dormancy, a combinational type resulting from multiple factors whose molecular mechanisms remain unclear. Methods: This study employed iTRAQ-based proteomics, transcriptomics, and hormone profiling to analyze three key germination stages (S1, pulp removal and initial imbibition. S2, radicle emergence through the seed coat. S3, transition phase between primary root elongation and cotyledon emergence). Results: Morphological observations indicated gradual endosperm weakening and embryo development during germination. Transcriptomics highlighted 30 enriched pathways, notably plant hormone signaling and starch and sucrose metabolism. Proteomics revealed consistent enrichment of FOG: RRM domain, aspartyl protease, and β-fructofuranosidase across comparisons. Hormone assays showed decreases in ABA, bioactive GAs, IAA, JA, and SA from S1 to S3, with a marked increase in the bioactive GAs/ABA ratio. Integrated omics emphasized metabolism and hormone signal transduction. Key enzymes in starch and sucrose metabolism (e.g., β-fructofuranosidase, α-xylosidase, β-D-xylosidase, and β-glucosidase) increased, supporting energy conversion and endosperm weakening. Conversely, ABA-related proteins (PYL4, PP2C) decreased. Sucrose synthase, involved in ABA-GA antagonism, also declined. Discussion: These results underscore synergistic endosperm weakening and hormonal regulation during P. cyrtonema seed germination, offering new insights for improving germination in species constrained by endosperm strength.
- Open Access
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 13, 1655760
A rapid approach for discriminating Ganoderma species using attenuated total reflectance–Fourier transform infrared (ATR-FTIR) spectroscopy integrated with chemometric analysis and convolutional neural network (CNN)
The issue of adulteration and misclassification of Ganoderma species is addressed in this research. In the study, we present a novel and comprehensive framework for Ganoderma authentication by analyzing attenuated total reflectance–Fourier transform infrared (ATR-FTIR) spectra using a combined approach of a chemometric analysis and deep learning (DL) with a convolutional neural network (CNN). The three Ganoderma species involved in this study were as follows: Ganoderma lucidum , Ganoderma sinense , and Ganoderma tsugae . Among chemometric models, orthogonal partial least squares discriminant analysis (OPLS-DA) yielded a high accuracy of 98.61%, a sensitivity of 97.92%, and a specificity of 98.96%. Additionally, the root-mean-squared error of estimation (RMSEE), root-mean-squared error of prediction (RMSEP), and root-mean-squared error of cross-validation (RMSECV) values for the OPLS-DA model were Ganoderma species. To further validate this combined approach, we aim to implement chemometric and CNN models in other medicinal herb authentication in the future.
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 13, 1655760
Open AccessA rapid approach for discriminating Ganoderma species using attenuated total reflectance–Fourier transform infrared (ATR-FTIR) spectroscopy integrated with chemometric analysis and convolutional neural network (CNN)
The issue of adulteration and misclassification of Ganoderma species is addressed in this research. In the study, we present a novel and comprehensive framework for Ganoderma authentication by analyzing attenuated total reflectance–Fourier transform infrared (ATR-FTIR) spectra using a combined approach of a chemometric analysis and deep learning (DL) with a convolutional neural network (CNN). The three Ganoderma species involved in this study were as follows: Ganoderma lucidum , Ganoderma sinense , and Ganoderma tsugae . Among chemometric models, orthogonal partial least squares discriminant analysis (OPLS-DA) yielded a high accuracy of 98.61%, a sensitivity of 97.92%, and a specificity of 98.96%. Additionally, the root-mean-squared error of estimation (RMSEE), root-mean-squared error of prediction (RMSEP), and root-mean-squared error of cross-validation (RMSECV) values for the OPLS-DA model were Ganoderma species. To further validate this combined approach, we aim to implement chemometric and CNN models in other medicinal herb authentication in the future.
- Open Access
- 21 September 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1420
In Vivo Antihypertensive and Ex Vivo Vasodilatory Studies of Taxifolin
Background: Hypertension is a leading cause of cardiovascular morbidity and mortality. Taxifolin has shown cardiovascular benefits, but its antihypertensive mechanisms remain poorly defined. This study aimed to comprehensively elucidate the molecular mechanisms underlying Taxifolin’s blood pressure-lowering effects by integrating network pharmacology, molecular docking, ex vivo functional studies, and in vivo validation. Methods: Network pharmacology and molecular docking prioritized targets. Ex vivo thoracic aortas were obtained from healthy male Sprague–Dawley (SD) rats, and rings (3–4 mm) were prepared for vasorelaxation studies. Pathway-specific inhibitors, Western blotting, and ELISA were used to investigate mechanisms. In vivo, spontaneously hypertensive rats (SHRs) received oral Taxifolin 15, 30, or 60 mg/kg once daily for 28 days; propranolol (80 mg/kg) served as the positive control. Results: Taxifolin produced robust vasorelaxation in endothelium-intact rings (Rmax ≈ 121%), falling to ~72% after denudation. Relaxation was attenuated by LY294002, ODQ, indomethacin, and glibenclamide. In SHR aorta, Taxifolin increased NO by ~132% and cGMP by ~1.9-fold and upregulated p-Akt and eNOS; LY294002 abolished these effects. In vivo, Taxifolin reduced systolic blood pressure by ≈60 mmHg without adverse changes in hematology, biochemistry, or body weight. Conclusions: Taxifolin lowers blood pressure through multiple vascular mechanisms consistent with PI3K/Akt/eNOS, NO–sGC–cGMP, COX-2/PGI2 and calcium-handling pathways, supporting its potential as a safe antihypertensive candidate.
- 21 September 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1420
Open AccessIn Vivo Antihypertensive and Ex Vivo Vasodilatory Studies of Taxifolin
Background: Hypertension is a leading cause of cardiovascular morbidity and mortality. Taxifolin has shown cardiovascular benefits, but its antihypertensive mechanisms remain poorly defined. This study aimed to comprehensively elucidate the molecular mechanisms underlying Taxifolin’s blood pressure-lowering effects by integrating network pharmacology, molecular docking, ex vivo functional studies, and in vivo validation. Methods: Network pharmacology and molecular docking prioritized targets. Ex vivo thoracic aortas were obtained from healthy male Sprague–Dawley (SD) rats, and rings (3–4 mm) were prepared for vasorelaxation studies. Pathway-specific inhibitors, Western blotting, and ELISA were used to investigate mechanisms. In vivo, spontaneously hypertensive rats (SHRs) received oral Taxifolin 15, 30, or 60 mg/kg once daily for 28 days; propranolol (80 mg/kg) served as the positive control. Results: Taxifolin produced robust vasorelaxation in endothelium-intact rings (Rmax ≈ 121%), falling to ~72% after denudation. Relaxation was attenuated by LY294002, ODQ, indomethacin, and glibenclamide. In SHR aorta, Taxifolin increased NO by ~132% and cGMP by ~1.9-fold and upregulated p-Akt and eNOS; LY294002 abolished these effects. In vivo, Taxifolin reduced systolic blood pressure by ≈60 mmHg without adverse changes in hematology, biochemistry, or body weight. Conclusions: Taxifolin lowers blood pressure through multiple vascular mechanisms consistent with PI3K/Akt/eNOS, NO–sGC–cGMP, COX-2/PGI2 and calcium-handling pathways, supporting its potential as a safe antihypertensive candidate.
- 18 September 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (11) , 2897-2910
Mechanistic insights into the synergistic vasodilatory actions of eupatorin, sinensetin, and 3’-hydroxy-5,6,7,4’-tetramethoxyflavone in ex vivo aortic ring model and their antihypertensive efficacy in in vivo rat model
Orthosiphon stamineus Benth, commonly used in Southeast Asia for its medicinal properties, is traditionally employed to treat diabetes and hypertension. Scientific research has validated that O. stamineus extract exhibits significant vasodilatory action on rat aorta. This effect is primarily due to the synergistic interaction among key compounds: eupatorin, sinensetin and 3’-hydroxy-5,6,7,4’-tetramethoxyflavone (TMF). Our previous publication identified the optimum formulation, G28, which contains eupatorin, sinensetin and TMF in the ratio of EC20:EC15:EC5. Therefore, the aim of this study was to investigate the antihypertensive effect and mechanism of action of formulation G28. In this study, aortic rings from spontaneously hypertensive rats (SHRs) and Sprague-Dawley (SD) rats were used to examine the vasodilation mechanisms. The antihypertensive effect of G28 was also assessed through repeated-dose administration in SHRs. G28 exhibited stronger vasorelaxant effects in SHR versus SD rat aortic rings, indicating higher potency under hypertensive conditions. The effect was partially endothelium-dependent, as endothelium removal reduced responses in both aortic rings. G28 retained efficacy with Nω-Nitro-1-arginine methyl ester, methylene blue and 1H-[1,2,4]Ox-adiazolol[4,3-α]quinoxaline-1-one, suggesting involvement of the NO/sGC/cGMP pathway. Additionally, G28’s effect diminished with glibenclamide, barium chloride, 4-aminopyrine and tetraethylammonium, indicating potassium channel involvements. The vasorelaxant effect was not significantly altered by indomethacin, atropine, or propranolol (in SD rats only), suggesting independence from the cyclooxygenase, beta-adrenergic (in SD rats only) and muscarinic pathways. G28 also reduced intracellular Ca²⁺ in vascular smooth muscle by antagonising voltage-gated calcium channel and Inositol triphosphate receptor. In vivo, G28 significantly reduced blood pressure in SHRs over 21 days of oral administration, underscoring its potential for hypertension control. G28 shows strong antihypertensive effects via NO/sGC/cGMP, potassium and calcium channels. Its sustained blood pressure reduction in SHRs highlights potential as a promising hypertension treatment option.
- 18 September 2025
- Published by Springer Nature in Hypertension Research
- Vol. 48 (11) , 2897-2910
Mechanistic insights into the synergistic vasodilatory actions of eupatorin, sinensetin, and 3’-hydroxy-5,6,7,4’-tetramethoxyflavone in ex vivo aortic ring model and their antihypertensive efficacy in in vivo rat model
Orthosiphon stamineus Benth, commonly used in Southeast Asia for its medicinal properties, is traditionally employed to treat diabetes and hypertension. Scientific research has validated that O. stamineus extract exhibits significant vasodilatory action on rat aorta. This effect is primarily due to the synergistic interaction among key compounds: eupatorin, sinensetin and 3’-hydroxy-5,6,7,4’-tetramethoxyflavone (TMF). Our previous publication identified the optimum formulation, G28, which contains eupatorin, sinensetin and TMF in the ratio of EC20:EC15:EC5. Therefore, the aim of this study was to investigate the antihypertensive effect and mechanism of action of formulation G28. In this study, aortic rings from spontaneously hypertensive rats (SHRs) and Sprague-Dawley (SD) rats were used to examine the vasodilation mechanisms. The antihypertensive effect of G28 was also assessed through repeated-dose administration in SHRs. G28 exhibited stronger vasorelaxant effects in SHR versus SD rat aortic rings, indicating higher potency under hypertensive conditions. The effect was partially endothelium-dependent, as endothelium removal reduced responses in both aortic rings. G28 retained efficacy with Nω-Nitro-1-arginine methyl ester, methylene blue and 1H-[1,2,4]Ox-adiazolol[4,3-α]quinoxaline-1-one, suggesting involvement of the NO/sGC/cGMP pathway. Additionally, G28’s effect diminished with glibenclamide, barium chloride, 4-aminopyrine and tetraethylammonium, indicating potassium channel involvements. The vasorelaxant effect was not significantly altered by indomethacin, atropine, or propranolol (in SD rats only), suggesting independence from the cyclooxygenase, beta-adrenergic (in SD rats only) and muscarinic pathways. G28 also reduced intracellular Ca²⁺ in vascular smooth muscle by antagonising voltage-gated calcium channel and Inositol triphosphate receptor. In vivo, G28 significantly reduced blood pressure in SHRs over 21 days of oral administration, underscoring its potential for hypertension control. G28 shows strong antihypertensive effects via NO/sGC/cGMP, potassium and calcium channels. Its sustained blood pressure reduction in SHRs highlights potential as a promising hypertension treatment option.
- 26 December 2024
- Published by Elsevier in Food Chemistry
- Vol. 470, 142661
Highly sensitive aggregation-induced electrochemiluminescence sensor for cadmium detection in Ganoderma lucidum
- 26 December 2024
- Published by Elsevier in Food Chemistry
- Vol. 470, 142661
Highly sensitive aggregation-induced electrochemiluminescence sensor for cadmium detection in Ganoderma lucidum
- Open Access
- 20 November 2024
- Published by Microbiology Society in Microbial Genomics
- Vol. 10 (11) , 001328
Pan-genomic characterization and structural variant analysis reveal insights into spore development and species diversity in Ganoderma
Understanding the genomic diversity and functional implications of Ganoderma species is crucial for elucidating their evolutionary history and biotechnological potential. Here, we present the first pan-genomic analysis of Ganoderma spp., combining five newly sequenced genomes with ten publicly available genomes. Our comprehensive comparative study unveiled a rich genomic landscape, identifying core genes shared among all Ganoderma strains and species-specific gene sets. Additionally, we identified structural variants impacting the expression of key genes, including insights into the MSH4 gene involved in DNA repair and recombination processes, which exhibits a 440 bp insertion in the promoter region and a leucine-to-serine mutation in the gene body, potentially increasing spore production in the S3 strain. Overall, our study provides valuable insights into the genomic architecture and functional diversity of Ganoderma, paving the way for further research on its evolutionary dynamics, biotechnological applications and pharmaceutical potential.
- 20 November 2024
- Published by Microbiology Society in Microbial Genomics
- Vol. 10 (11) , 001328
Open AccessPan-genomic characterization and structural variant analysis reveal insights into spore development and species diversity in Ganoderma
Understanding the genomic diversity and functional implications of Ganoderma species is crucial for elucidating their evolutionary history and biotechnological potential. Here, we present the first pan-genomic analysis of Ganoderma spp., combining five newly sequenced genomes with ten publicly available genomes. Our comprehensive comparative study unveiled a rich genomic landscape, identifying core genes shared among all Ganoderma strains and species-specific gene sets. Additionally, we identified structural variants impacting the expression of key genes, including insights into the MSH4 gene involved in DNA repair and recombination processes, which exhibits a 440 bp insertion in the promoter region and a leucine-to-serine mutation in the gene body, potentially increasing spore production in the S3 strain. Overall, our study provides valuable insights into the genomic architecture and functional diversity of Ganoderma, paving the way for further research on its evolutionary dynamics, biotechnological applications and pharmaceutical potential.